Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
与接受其他生物制剂或传统合成DMARD治疗的类风湿性关节炎患者相比,接受托珠单抗治疗的类风湿性关节炎患者发生下肠穿孔的风险更高
期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2016-209773
Strangfeld, A; Richter, A; Siegmund, B; Herzer, P; Rockwitz, K; Demary, W; Aringer, M; Meißner, Y; Zink, A; Listing, J